Marc Rubin, Director at GALECTIN THERAPEUTICS INC (GALT), bought 7,000 shares at $1.85 ($13K) on 2017-12-08, disclosed to the SEC on 2017-12-08.
Open-market purchase of $13k GALT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| TTNP | BUY | 2018-09-25 | $100K | — | Filing → |
| GALT | SELL | 2018-09-06 | $78K | — | Filing → |
| GALT | SELL | 2018-09-04 | $353K | — | Filing → |